drugset / Trial / NCT01022112

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

NCT01022112

Phase 2 Completed 383 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.

Timeline

Start
2009-11
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule Oral